2-(3-氯吡啶-2-基)乙酸甲酯 | 1092477-86-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-(3-氯吡啶-2-基)乙酸甲酯
• 英文名称: methyl (3-chloro-2-pyridinyl)acetate
• 英文别名: Methyl 2-(3-chloropyridin-2-yl)acetate
• CAS: 1092477-86-5
• 化学式: C₈H₈ClNO₂
• 分子量: 185.61
• InChiKey: PUTYVQIHGXKLHE-UHFFFAOYSA-N

物化性质

• 沸点：
  239.0±25.0 °C(Predicted)
• 密度：
  1.259±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  2-(3-氯吡啶-2-基)乙酸甲酯 在 4-乙酰氨基苯磺酰叠氮 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 乙腈 为溶剂， 以78%的产率得到Methyl 4-chlorotriazolo[1,5-a]pyridine-3-carboxylate
  参考文献：
  名称：

  [EN] UREA DERIVATIVES AND USES THEREOF
  [FR] DÉRIVÉS DE L'URÉE ET LEURS UTILISATIONS

  摘要：

  公开号：

  WO2014201127A3
• 作为产物：
  描述：

  2,3-二氯吡啶 在 盐酸 、 甲醇 、 正丁基锂 、 水 作用下， 以 四氢呋喃 、 hexanes 为溶剂， 反应 12.25h， 生成 2-(3-氯吡啶-2-基)乙酸甲酯
  参考文献：
  名称：

  WO2008/148853

  摘要：

  公开号：

文献信息

• N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR
  申请人：Bernasconi Giovanni

  公开号：US20100286152A1

  公开（公告）日：2010-11-11

  The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof,

  本发明涉及公式（I）的新化合物或其药学上可接受的盐或溶剂。
• Urea derivatives and uses thereof
  申请人：Kala Pharmaceuticals, Inc.

  公开号：US10316022B2

  公开（公告）日：2019-06-11

  The present invention provides novel compounds of any one of Formulae (I)-(III), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of Formula (I)-(III) and pharmaceutical compositions thereof that are mucus penetrating. The invention also provides methods and kits for using the inventive compounds, and pharmaceutical compositions thereof, for treating and/or preventing diseases associated with abnormal or pathological angiogenesis and/or aberrant signaling of a growth factor (e.g., vascular endothelial growth factor (VEGF)), such as proliferative diseases (e.g., cancers, benign neoplasms, inflammatory diseases, autoimmune diseases) and ocular diseases (e.g., macular degeneration, glaucoma, diabetic retinopathy, retinoblastoma, edema, uveitis, dry eye, blepharitis, and post-surgical inflammation) in a subject in need thereof.

  本发明提供了式(I)-(III)中任一项的新型化合物及其药物组合物。本发明还提供了由式（I）-（III）化合物及其药物组合物组成的具有粘液渗透性的颗粒（如纳米颗粒）。本发明还提供了使用本发明化合物及其药物组合物治疗和/或预防与异常或病理性血管生成和/或生长因子（如血管内皮生长因子（VEGF））异常信号转导有关的疾病的方法和试剂盒，如增殖性疾病（如、如增殖性疾病（如癌症、良性肿瘤、炎症性疾病、自身免疫性疾病）和眼部疾病（如黄斑变性、青光眼、糖尿病视网膜病变、视网膜母细胞瘤、水肿、葡萄膜炎、干眼症、睑缘炎和手术后炎症）。
• WO2008/148853
  申请人：——

  公开号：——

  公开（公告）日：——
• UREA DERIVATIVES AND USES THEREOF
  申请人：Kala Pharmaceuticals, Inc.

  公开号：US20150072986A1

  公开（公告）日：2015-03-12

  The present invention provides novel compounds of any one of Formulae (I)-(III), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of Formula (I)-(III) and pharmaceutical compositions thereof that are mucus penetrating. The invention also provides methods and kits for using the inventive compounds, and pharmaceutical compositions thereof, for treating and/or preventing diseases associated with abnormal or pathological angiogenesis and/or aberrant signaling of a growth factor (e.g., vascular endothelial growth factor (VEGF)), such as proliferative diseases (e.g., cancers, benign neoplasms, inflammatory diseases, autoimmune diseases) and ocular diseases (e.g., macular degeneration, glaucoma, diabetic retinopathy, retinoblastoma, edema, uveitis, dry eye, blepharitis, and post-surgical inflammation) in a subject in need thereof.
• Urea Derivatives and Uses Thereof
  申请人：Kala Pharmaceuticals, Inc.

  公开号：US20190284172A1

  公开（公告）日：2019-09-19

  The present invention provides novel compounds of any one of Formulae (I)-(III), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of Formula (I)-(III) and pharmaceutical compositions thereof that are mucus penetrating. The invention also provides methods and kits for using the inventive compounds, and pharmaceutical compositions thereof, for treating and/or preventing diseases associated with abnormal or pathological angiogenesis and/or aberrant signaling of a growth factor (e.g., vascular endothelial growth factor (VEGF)), such as proliferative diseases (e.g., cancers, benign neoplasms, inflammatory diseases, autoimmune diseases) and ocular diseases (e.g., macular degeneration, glaucoma, diabetic retinopathy, retinoblastoma, edema, uveitis, dry eye, blepharitis, and post-surgical inflammation) in a subject in need thereof.